Something new on the horizon!

[Mgtd]

urologytimes.com/view/fda-c...

[street-air]

the most succinct paragraph I could find on this new one is

"While both 225Ac-PSMA and 177Lu-PSMA have shown promising results in clinical studies, 225Ac-PSMA is a relatively newer agent that is still being evaluated in ongoing clinical trials. 225Ac-based targeted alpha-radiation therapy may be more effective for disseminated metastatic disease due to its short range, high LET, and reduced damage to healthy tissues compared to 177Lu-PSMA including red bone marrow. "

It is an alpha particle emitter not a beta emitter but operates similarly to LU177.